List of Antibodies Companies in Ireland - 9

At Altratech, we are moving serology and the monitoring of viral contagious diseases out of the laboratory to the point-of-care and community clinics. We are a team of twenty scientists and engineers, including nine PhDs, from cross-functional backgrounds of molecular biology, organic and synthetic chemistry, microfluidics, engineering and CMOS semiconductor technologies. With over 200 years of combined experience, our vision is to create portable high-performance diagnostics which will enable the next generation of decentralised connected healthcare and wellbeing.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Keltic Pharma is based in a world leading laboratory in Glasgow with our highly skilled team of industrial scientists and leading academics. We work alongside commercial partners and universities to deploy novel innovative technologies in the pursuit of next generation drugs for unmet clinical needs.

Established in 2009, MyBio is a premium supplier of research products, technology, and expertise. We're at the forefront of innovation, enabling the science that's changing lives for the better. Our clients include a range of life scientists based in research laboratories from a variety of sectors. For Academia As scientists ourselves, we understand the challenges that are faced by researchers every day. From needing that all important reagent as quickly as possible, to having to keep an eye on budget – we can help every step of the way too. Quality & Support Our partners are carefully selected, meaning that the products they produce are of the highest quality. As scientists, we only supply tools and equipment that we would use ourselves. Time is of the essence for a busy researcher, therefore we offer full troubleshooting support for when things are not quite going to plan. For Pharma We are an established supplier of custom products for the pharmaceutical industry, with a team of dedicated scientists experienced in the drug discovery and development process. Using our expertise, we are able to work closely with pharmaceutical companies confidentially, tailoring solutions to their unique problems through our well-established ties with our suppliers. We are able to provide our clients with truly customized products that allow for the efficient conversion of potential API leads into candidates and through to established therapeutic drugs. For Suppliers We are always looking to evolve alongside new partners, and have a proud record of delivering strong growth for our suppliers, owing to our knowledge of our customers’ challenges, and our experience of the market on a national level. MyBio are innovative and ambitious, and we are proud of our reputation as one of Ireland’s most trusted suppliers, helping manufacturers penetrate the market and deliver their trusted innovations to laboratories nationwide.

ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits and equipment. The quality and efficacy of our products is essential to ensure clinicians and patients are provided with a reliable, safe and robust method of diagnosis. It’s essential that we are always cognisant that a patient may receive a life changing diagnosis from one of our products. Trinity Biotech is a company which is made up of a wide range of people from different backgrounds and experience. Our goal is to have a friendly, inclusive and fun place to work which also supports the needs of our business. Working at Trinity Biotech means working on a range of items which provides great experience and keeps our roles interesting, challenging and rewarding. Our size makes us an organisation which is large enough to ensure there is a wide range of activities, projects and day to day variety.